Browse the evidence

Cagrisema produced significantly greater percentage weight loss than semaglutide with a mean difference of -7.47% (95% CI: -10.58, -4.36; p < 0.001).

Cagrisema may be a more effective option for weight loss in obese patients compared to semaglutide.

Cagrilintide monotherapy weight loss was comparable to semaglutide.

Cagrilintide may be a viable alternative to semaglutide for weight management in obese patients.

Cagrisema is safe and has a comparable side effect profile to semaglutide.

Cagrisema can be considered a safe option for weight management in obese patients.

Meal replacements (MRs) led to a greater reduction in body weight by -1.38 kg compared to conventional food-based weight loss diets.

Incorporating meal replacements can be an effective strategy for weight loss in individuals at risk of metabolic syndrome.

MRs resulted in a reduction in body mass index (BMI) by -0.56 kg/m2 compared to conventional diets.

Using meal replacements can help reduce BMI in at-risk populations.

The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.

Semaglutide may lead to significant weight loss in patients with MASH.

Intensive lifestyle modification decreased the incidence of diabetes by 6.2 cases per 100 person-years during a 3-year period.

Encouraging lifestyle changes can significantly reduce the risk of developing diabetes.

Treatment with once-weekly injectable semaglutide resulted in a mean change in body weight of -13.7% compared to -3.2% with placebo (P<0.001).

Semaglutide may be an effective treatment for weight loss in obese individuals with knee osteoarthritis.

Higher weight loss was associated with a lower hazard of discontinuation for both patients with and without type 2 diabetes.

Encouraging weight loss may improve adherence to GLP-1 RA therapy.

Substitution of low- and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) was associated with a reduction in body weight by 1.06 kg.

Practitioners may consider recommending LNCSBs as a substitute for SSBs to aid in weight management.

Substitution of LNCSBs for SSBs was associated with a reduction in body mass index (BMI) by 0.32.

Practitioners may use LNCSBs to help reduce BMI in at-risk populations.

Nutritionally inadequate dietary intake is a leading contributor to chronic cardiometabolic diseases.

Practitioners should focus on improving dietary intake to prevent chronic diseases.

Bariatric surgery results in a mean weight loss of −22.68 kg compared to GLP-1 receptor agonists.

Bariatric surgery may be more effective than GLP-1 receptor agonists for significant weight loss.

Lifestyle and behavioral modification for obesity and/or PDWG in psychiatric populations is effective.

Encouraging lifestyle changes can be beneficial for patients experiencing PDWG.

Among the 62 associations between diet and cardiometabolic disease (CMD), 10 foods, 3 beverages, and 12 nutrients had at least probable evidence of associations with coronary heart disease, stroke, and/or diabetes.

Dietary guidance can be informed by these associations to help reduce the risk of CMD.

Twins on the vegan diet experienced a significant mean decrease in body weight of -1.9 kg after 8 weeks.

Clinicians may recommend a vegan diet for weight loss in patients.

Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.

Practitioners can consider cagrilintide-semaglutide as an effective treatment for weight management in this population.

More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more.

Cagrilintide-semaglutide may be particularly effective for achieving clinically significant weight loss.

Semaglutide is associated with significant weight reductions primarily due to fat mass loss.

Practitioners can expect semaglutide to primarily aid in fat loss for overweight or obese patients.

Endoscopic sleeve gastroplasty (ESG) added 0.06 quality-adjusted life-years (QALYs) and reduced total cost by $33,583 relative to semaglutide.

This indicates that ESG not only provides health benefits but also reduces overall treatment costs.

A target of 10–15% weight loss is recommended for people with BMI 30–40 kg/m2 or abdominal obesity without complications.

Practitioners should aim for a 10-15% weight loss in this patient group.

For people with BMI 30–40 kg/m2 or abdominal obesity and complications, a weight loss target of 10–15% body weight is recommended.

Practitioners should target a 10-15% weight loss for this patient group.

A weight loss target of > 15% is recommended for those with BMI > 40 kg/m2 and complications.

Practitioners should aim for more than 15% weight loss in this patient group and consider referral to specialists.

If all eligible individuals received medically tailored meals (MTMs), an estimated 1,594,000 hospitalizations could potentially be averted in 1 year.

Healthcare providers should consider the potential benefits of MTMs in reducing hospitalizations for eligible patients.